Clinical Trials Logo

Hepatomegaly clinical trials

View clinical trials related to Hepatomegaly.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00565097 Completed - Liver Diseases Clinical Trials

Lanreotide as Treatment of Polycystic Livers

LOCKCYST
Start date: October 2007
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

NCT ID: NCT00426153 Completed - Liver Diseases Clinical Trials

Octreotide in Severe Polycystic Liver Disease

Start date: January 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence indicates that this drug is safe and non-toxic in other disease states. Treatment with this drug holds promise not only for individuals with liver involvement, but also for many more patients with polycystic kidney disease.